DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tivantinib
Tivantinib
Daiichi Sankyo Group Value Report 2019
Targeted Therapies in Melanoma: Knowledge, Resistance And
A Phase I Dose Escalation Study of Tivantinib (ARQ 197) in Adult
A Systematic Review and Meta-Analysis Comparing The
Crusader Q2 2020 Research Edition Download
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Recent Advances in the Management of Advanced Non–Small-Cell Lung Cancer Charu Aggarwal, MD, MPH, and Corey J
A Phase I Trial of Topotecan Plus Tivantinib in Patients with Advanced Solid Tumors
Profile of Tivantinib and Its Potential in the Treatment of Hepatocellular Carcinoma: the Evidence to Date
Clinical Trial Protocol
Phase 1B/2 Trial of Tepotinib in Sorafenib Pretreated Advanced Hepatocellular Carcinoma with MET Overexpression
Exploring Receptor Tyrosine Kinases-Inhibitors in Cancer
Emerging Drugs for Prostate Cancer
Exploiting MET Dysregulation in EGFR-Addicted Non-Small-Cell Lung Carcinoma: a Further Step Toward Personalized Medicine
Novel Agents in Development for Advanced Non-Small Cell Lung Cancer
Clinical Development of C-MET Inhibition in Hepatocellular Carcinoma
Top View
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy Nehme El-Hachem1,2, Deena M.A
Randomised Phase 1B/2 Trial of Tepotinib Vs Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma with MET Overexpression
Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
Computationally Predicting Clinical Drug Combination Efficacy With
WO 2017/203532 Al 30 November 2017 (30.11.2017) W !P O PCT
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Lung Cancer
International Nonproprietary Names for Pharmaceutical Substances (INN)
Tivantinib, a C-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Dctd Programs and Initiatives (2013-2017) Biometric Research Program 46
Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of the Art and Future Directions
View a Copy of This Licence, Visit
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Resistance to Molecularly Targeted Therapies in Melanoma
C-MET Inhibition: Novel Treatment for Sporadic and MEN1-Associated GEP Nets
1078-0432.CCR-19-1895.Full.Pdf
Attachment: Extract from Clinical Evaluation: Cabozantinib
125084Orig1s277, S280
Sorafenib Induces Ferroptosis in Human Cancer Cell Lines Originating from Different Solid Tumors
High Content Screening and Proteomic Analysis Identify a Kinase Inhibitor That Rescues Pathological Phenotypes in a Patient-Deri
WO 2016/192680 Al 8 December 2016 (08.12.2016) P O P C T
Downloaded at Via “Supplementary Table 3 Drug
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Clinical Cancer Cancer Therapy: Clinical Research
Privileged Communication S
The Efficacy and Safety of Tivantinib in the Treatment of Solid Tumors: a Systematic Review and Meta-Analysis
NCI Protocol #: 9165 Local Protocol #: 12-1359
Therapeutic Potential of Angiogenesis Inhibitor Mixtures in Cancer Treatment
WO 2017/106656 Al 22 June 2017 (22.06.2017) W P O P C T
Capmatinib and Gefitinib Combination Therapy: Will EGFR-Mutated MET-Dysregulated NSCLC “Capitulate”?
The Role of C-MET Inhibitors in Advanced Hepatocellular Carcinoma: Now and Future